IOBT IO Biotech
- 1.430
- -0.010-0.69%
IO Biotech News
IO Biotech Is Maintained at Buy by HC Wainwright & Co.
IO Biotech Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The IO Biotech (IOBT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $8.00 to $12.00.
HC Wainwright & Co. : The IO Biotech (IOBT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $8.00 to $12.00.
HC Wainwright & Co. Maintains Buy on IO Biotech, Raises Price Target to $12
HC Wainwright & Co. analyst Emily Bodnar maintains IO Biotech (NASDAQ:IOBT) with a Buy and raises the price target from $8 to $12.
Optimistic Buy Rating for IO Biotech Amidst Promising Clinical Trial Progress and Accelerated PFS Data Timeline
IO Biotech(IOBT.US) 10% Shareholder Sells US$802.5K in Common Stock
$IO Biotech(IOBT.US)$ 10% Shareholder Novo Holdings A/S sold 658.81K shares of common stock on May 10, 2024 at an average price of $1.2181 for a total value of $802.5K.Source: Announcement What is sta
Analysts Are Bullish on These Healthcare Stocks: IO Biotech (IOBT), Iterum Therapeutics (ITRM)
IO Biotech | 10-Q: Quarterly report
IO Biotech 1Q Loss $19.5M >IOBT
IO Biotech 1Q Loss $19.5M >IOBT
IO Biotech 1Q Loss/Shr 30c >IOBT
IO Biotech 1Q Loss/Shr 30c >IOBT
Form 144 | IO Biotech(IOBT.US) 10% Stockholder Proposes to Sell 988.21K in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $IO Biotech(IOBT.US)$ 10% Stockholder Novo Holdings A/S intends to sell 658.81K shares of its common stock on May 10, with a total market value of approximately $988.21
IO Biotech Board Member Jack Nielsen Resigns Due to Health
IO Biotech Presents New Data For Cancer Vaccine Candidate, IO102-IO103, At AACR 2024
IO Biotech Presents New Data For Cancer Vaccine Candidate, IO102-IO103, At AACR 2024
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
IO Biotech (Nasdaq: IOBT) today shared new data related to the company's lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.
IO Biotech: Miyara Will Be Based in the US, Reporting to CEO, Mai-Britt Zocca >IOBT
IO Biotech: Miyara Will Be Based in the US, Reporting to CEO, Mai-Britt Zocca >IOBT
IO Biotech Appoints Faical Miyara Chief Business Officer >IOBT
IO Biotech Appoints Faical Miyara Chief Business Officer >IOBT
IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersSCWorx (NASDAQ:WORX) stock increased by 60.8% to $2.75 during Wednesday's after-market session. The market value of their outstanding shares is at $3.3 million. IO Biotech (NASDAQ:IOBT) stock i
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage
HC Wainwright & Co. Reiterates Buy on IO Biotech, Maintains $8 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates IO Biotech with a Buy and maintains $8 price target.
IO Biotech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/06/2024 393.83% HC Wainwright & Co. → $8 Reiterates Buy → Buy 09/28/2023 517.28% Piper Sandler → $10 In
Analysis
Price Target
No Data
